CLINICAL TRIALS PROFILE FOR CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

All Clinical Trials for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00020865 ↗	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia	Unknown status	National Cancer Institute (NCI)	Phase 3	2001-09-01	RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer.
NCT00020865 ↗	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia	Unknown status	Jonsson Comprehensive Cancer Center	Phase 3	2001-09-01	RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer.
NCT00044759 ↗	Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	1969-12-31	To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
NCT00137787 ↗	Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases	Completed	Bayer	Phase 3	2005-04-01	The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.
NCT00137787 ↗	Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases	Completed	Center for Supporting Hematology-Oncology Trials	Phase 3	2005-04-01	The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.
NCT00358202 ↗	Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia	Completed	Elan Pharmaceuticals	Phase 4	2002-03-01	Randomized trial of nursing home residents with pneumonia to assess if intramuscular cefepime is a safe, efficacious, and cost-effective alternative to once daily intramuscular ceftriaxone for the treatment of elderly nursing home residents who develop pneumonia and do not require hospitalization.
NCT00358202 ↗	Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia	Completed	CPL Associates	Phase 4	2002-03-01	Randomized trial of nursing home residents with pneumonia to assess if intramuscular cefepime is a safe, efficacious, and cost-effective alternative to once daily intramuscular ceftriaxone for the treatment of elderly nursing home residents who develop pneumonia and do not require hospitalization.

Clinical Trial Conditions for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

Condition Name

Condition Name for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
Intervention	Trials
Febrile Neutropenia	5
Complicated Urinary Tract Infection	5
Acute Pyelonephritis	5
Healthy Subjects	3

Condition MeSH

Condition MeSH for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
Intervention	Trials
Infections	17
Communicable Diseases	15
Infection	14
Urinary Tract Infections	11

Clinical Trial Locations for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

Trials by Country

Trials by Country for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
Location	Trials
United States	81
Spain	10
Poland	8
India	8
Brazil	6

Trials by US State

Trials by US State for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
Location	Trials
Texas	10
California	8
Florida	6
New York	5
Pennsylvania	5

Clinical Trial Progress for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
PHASE4	2
PHASE1	1
Phase 4	14

Clinical Trial Status

Clinical Trial Status for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	28
Not yet recruiting	10
Recruiting	8

Clinical Trial Sponsors for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
Sponsor	Trials
Wockhardt	7
M.D. Anderson Cancer Center	5
Venatorx Pharmaceuticals, Inc.	4

Sponsor Type

Sponsor Type for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
Sponsor	Trials
Other	61
Industry	38
NIH	6

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER Market Analysis and Financial Projection

Last updated: April 28, 2026

Cefepime Hydrochloride in Plastic Container: Clinical Trials Update, Market Analysis, and Projection

What clinical trial activity exists for cefepime hydrochloride in a plastic container?

No complete, decision-grade trial dataset can be produced from the information available in this session. A clinical trials update requires verifiable identifiers tied to the specific formulation and container closure system (e.g., NCT numbers and protocol links for the exact “plastic container” presentation of cefepime hydrochloride), plus endpoints (sterility, potency over shelf-life, leachables/particulates, stability under stress, and clinical outcomes where relevant). That evidence is not present here, so a precise trial-by-trial update cannot be generated.

What market exists for cefepime hydrochloride packaged in plastic containers?

No complete, decision-grade market dataset can be produced for the specific product descriptor “cefepime hydrochloride in plastic container” from the information available in this session. A defensible market analysis needs at least: (1) product-level net sales by geography and channel, (2) pricing by package format (bag vs vial), (3) inclusion/exclusion criteria for other cefepime presentations (vials, different concentrations, different container types), and (4) competitive share tied to the exact packaging system. Those inputs are not available here.

How should investors and R&D teams project demand for this formulation?

No projection can be produced without container-specific market sizing, pricing, and adoption assumptions. Projections must anchor to formulation- and container-specific drivers, such as:

• conversion of hospital IV workflows from vials to plastic bags (or vice versa)
• pharmacy automation compatibility and handling costs
• reported stability and quality attributes tied to the plastic system
• procurement mix by geography and tender preferences

Those drivers require evidence that is not present in this session.

What can be stated with proof from this session

None. This request requires product-, trial-, and market-level facts that are not included here.

---

Key Takeaways

• A clinical trials update cannot be produced because no trial-level evidence tied to “cefepime hydrochloride in plastic container” is available in this session.
• A market analysis and forecast cannot be produced because no product-level sales, pricing, share, or packaging-specific adoption data is available in this session.
• Projection modeling requires container-specific demand drivers and baseline market sizing that are not present here.

---

FAQs

1. Does cefepime have clinical trials for plastic containers?
   Not assessable here without formulation-specific trial identifiers and endpoints tied to the plastic container presentation.

2. Is the market for cefepime driven more by API demand or by packaging format?
   The balance depends on hospital procurement and workflow adoption, but packaging-format attribution cannot be quantified from this session.

3. What endpoints matter most for plastic container qualification?
   Commonly: stability (potency), particulate matter, sterility assurance, and leachables. Clinical efficacy trials are not always required if bioequivalence and stability/regulatory requirements are met.

4. Can cefepime forecasts use total cefepime market data?
   Only if the packaging mix is quantified. Without plastic-container-specific share and pricing, a reliable forecast cannot be constructed.

5. What would a decision-grade forecast require?
   Plastic-container-specific baseline demand, pricing, geography, conversion rates from other presentations, and competitor share, none of which are included here.

---

Cited Sources

[1]